Bluebird Care has been acquired by Interim Healthcare Inc.
US-based care-at-home franchisor Interim Healthcare Inc. has acquired Bluebird Care, based in the UK, a national provider of care in the home. Financial details have not been provided.
Bluebird Care offers a unique service of tailored care visits from 30 minutes to full live-in support. The company has nearly 200 offices in the UK and the Republic of Ireland.
Founded in 1966, Interim Healthcare has more than 300 independently owned and operated franchise locations providing a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing services.
UK-based Oaklins Smith & Williamson, assisted by the team in Los Angeles, advised the seller in this transaction.
Talk to the deal team
Gary S. Rabishaw
Oaklins Intrepid
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more